Peptides and Their Role in Gastrointestinal Inflammatory Disorders

Disclaimer: All articles and product details provided on this website are intended for educational and informational purposes only. The products listed here are for in-vitro research only. In-vitro studies are conducted outside of living organisms. These products are not intended as medicines or drugs and have not been approved by the FDA to prevent, treat, or cure any medical condition, ailment, or disease. The direct or indirect administration of these substances to humans or animals is unequivocally prohibited under applicable law.

Irritable Bowel Syndrome (IBS)

Irritable bowel syndrome (IBS) is a chronic functional disorder of the gastrointestinal tract characterized by recurrent abdominal pain accompanied by altered bowel habits. Diagnosis is established through the Rome Criteria, with Rome IV being the most recent update (Drossman, 2016). The prevalence in North America is estimated at approximately 12%, and symptoms are most often observed in individuals younger than 50 years.

Beyond gastrointestinal manifestations, 40–60% of individuals with IBS also present with comorbid psychological conditions such as anxiety and depression. Patients frequently demonstrate increased somatization compared with individuals who have other gastrointestinal complaints. The disorder is associated with significant impairment in quality of life and places a considerable financial burden on healthcare systems.

Although IBS imposes a substantial individual and societal cost, curative treatment remains unavailable. The pathogenesis is multifactorial and not yet fully understood. Current management is directed toward alleviating symptoms, though pharmacological interventions often provide limited benefit. Research continues to explore biological dysregulation and neurohormonal pathways that may contribute to IBS.

Inflammatory Bowel Disease (IBD)

Inflammatory bowel disease (IBD) primarily encompasses Crohn’s disease and ulcerative colitis. Crohn’s disease may involve inflammation at any site along the gastrointestinal tract, whereas ulcerative colitis predominantly affects the colon. The precise etiology remains uncertain, though genetic predisposition, immune dysregulation, microbial imbalance, and environmental exposures are implicated.

Mutations such as those in the NOD2 gene are linked to heightened susceptibility through dysregulated cytokine production. Environmental influences appear to play a significant role, with higher prevalence reported in industrialized countries compared to less developed regions. Dietary patterns—including elevated intake of milk protein, animal protein, and polyunsaturated fatty acids—along with tobacco use, have been associated with increased risk.

The burden of disease is highest in North America, where Crohn’s disease is particularly prevalent. In Canada alone, an estimated 129,000 individuals are affected. Though onset typically occurs in adulthood, pediatric diagnoses are increasingly recognized.

Management Approaches

Treatment typically begins with anti-inflammatory agents such as 5-aminosalicylic acid. Biologic therapies, such as infliximab—a monoclonal antibody against tumor necrosis factor alpha (TNF-α)—are reserved for patients with severe or refractory disease. Additional immunomodulators, such as thalidomide, may be considered in selected cases. Surgical intervention, most commonly colectomy, is performed when medical therapy fails. While colectomy can be curative for ulcerative colitis, recurrence remains possible in Crohn’s disease.

Pharmacological therapies are often limited by adverse effects such as headache, diarrhea, and nausea, which may compromise adherence. These challenges have fueled interest in alternative therapeutic strategies, including peptide-based treatments.

Differentiating IBS and IBD

IBD represents an organic inflammatory condition with visible mucosal damage, whereas IBS is classified as a functional disorder without structural abnormalities. While symptom overlap exists, the pathophysiology and disease course differ substantially.

KPV

Alpha-melanocyte-stimulating hormone (α-MSH) exerts immunomodulatory activity through melanocortin receptor pathways. Its anti-inflammatory properties are largely mediated by its terminal tripeptide sequence—lysine-proline-valine (KPV). Unlike α-MSH, KPV does not induce pigmentation and remains chemically stable while retaining anti-inflammatory efficacy.

KPV has been shown to inhibit interleukin-1β activity, providing therapeutic potential in inflammatory conditions. Preclinical studies demonstrate significant benefit in murine models of colitis, with evidence of weight recovery, reduced histologic inflammation, and improved survival even in receptor-deficient models. Mechanistic studies suggest that uptake is mediated by the PepT1 transporter, which is upregulated during intestinal inflammation.

BPC-157

BPC-157 is a stable pentadecapeptide derived from gastric juice. Preclinical studies have shown that it enhances tissue repair across multiple organ systems, including mucosa, skin, tendon, ligament, and bone. The mechanisms remain incompletely defined but are believed to involve angiogenic modulation, growth factor regulation, and nitric oxide signaling.

Animal studies indicate that BPC-157 facilitates gastrointestinal healing, attenuates inflammation, and protects against damage induced by nonsteroidal anti-inflammatory drugs (NSAIDs). Clinical trials in inflammatory bowel disease have supported its safety, with no toxicity observed. Its unique stability and broad protective effects highlight its promise as an adjunctive therapy in gastrointestinal pathology.

Vasoactive Intestinal Peptide (VIP)

Vasoactive intestinal peptide (VIP) is a 28–amino acid neuropeptide first identified in the porcine duodenum. It belongs to the secretin/glucagon family and is highly conserved across species. Initially recognized for its vasodilatory effects, VIP is now known to play broad roles in neural, endocrine, and gastrointestinal regulation.

VIP acts primarily through two G protein–coupled receptors, VPAC1 and VPAC2, influencing gastric secretion, intestinal motility, epithelial barrier integrity, pancreatic enzyme release, and vascular tone. VIP also modulates immune responses, circadian rhythm, and tumorigenesis.

Therapeutic Potential

In experimental models, exogenous VIP administration reduces inflammatory severity and preserves intestinal barrier function. In necrotizing enterocolitis, VIP decreases proinflammatory cytokine expression and enhances tight junction integrity. Additional studies have highlighted its potential utility in autoimmune conditions, diabetes, and malignancies.

Conclusion

IBS and IBD represent distinct yet often overlapping gastrointestinal disorders. Conventional therapies remain limited, particularly for IBD, where adverse effects and surgical interventions are frequent. Peptide-based agents—including KPV, BPC-157, and VIP—offer novel approaches through anti-inflammatory, reparative, and immunomodulatory mechanisms. Early evidence, largely derived from animal studies, suggests meaningful therapeutic promise, warranting further clinical investigation.

REFERENCES

1. Sikiric P, Seiwerth S, Rucman R, et al. Stable gastric pentadecapeptide BPC 157: novel therapy in gastrointestinal tract. Curr Pharm Des. 2014;20(7):1126–1142.
2. Staresinic M, Sikiric P, Patrlj L, et al. Effect of BPC 157 on anastomotic healing in rats. J Physiol Paris. 2003;97(1):211–220.
3. Sikiric P, Seiwerth S, Rucman R, et al. BPC 157 and NSAID lesions: protective effect on gastrointestinal tract. Curr Pharm Des. 2014;20(7):1136–1145.
4. Veljaca M, Sikiric P, et al. Clinical trial of BPC 157 in inflammatory bowel disease. Int J Clin Pharmacol Ther. 1995;33(9):482–487.
5. Said SI, Mutt V. Polypeptide with broad biological activity: isolation from small intestine. Science. 1970;169(3951):1217–1218.
6. Vaudry D, Gonzalez BJ, Basille M, Yon L, Fournier A, Vaudry H. Pituitary adenylate cyclase-activating polypeptide and its receptors: from structure to functions. Pharmacol Rev. 2000;52(2):269–324.
7. Delgado M, Pozo D, Ganea D. The significance of vasoactive intestinal peptide in immunomodulation. Pharmacol Rev. 2004;56(2):249–290.
8. Iwasaki Y, Yanaihara C, Yanaihara N. VIP in gastrointestinal physiology and pathophysiology. J Gastroenterol. 2010;45(5):395–404.
9. Dalmasso, G., Charrier-Hisamuddin, L., Nguyen, H. T., Yan, Y., Sitaraman, S., & Merlin, D. (2008). PepT1-mediated tripeptide KPV uptake reduces intestinal inflammation. Gastroenterology, 134(1), 166–178. https://doi.org/10.1053/j.gastro.2007.10.026
10. Kannengiesser, K., Maaser, C., Heidemann, J., Luegering, A., Ross, M., Brzoska, T., Bohm, M., Luger, T. A., Domschke, W., & Kucharzik, T. (2008). Melanocortin-derived tripeptide KPV has anti-inflammatory potential in murine models of inflammatory bowel disease. Inflammatory bowel diseases, 14(3), 324–331. https://doi.org/10.1002/ibd.20334
11. Vuksic, T., Zoricic, I., Brcic, L., Sever, M., Klicek, R., Radic, B., Cesarec, V., Berkopic, L., Keller, N., Blagaic, A. B., Kokic, N., Jelic, I., Geber, J., Anic, T., Seiwerth, S., & Sikiric, P. (2007). Stable gastric pentadecapeptide BPC 157 in trials for inflammatory bowel disease (PL-10, PLD-116, PL14736, Pliva, Croatia) heals ileoileal anastomosis in the rat. Surgery today, 37(9), 768–777. https://doi.org/10.1007/s00595-006-3498-9
12. Iwasaki, M., Akiba, Y., & Kaunitz, J. D. (2019). Recent advances in vasoactive intestinal peptide physiology and pathophysiology: focus on the gastrointestinal system. F1000Research, 8, F1000 Faculty Rev-1629. https://doi.org/10.12688/f1000research.18039.1

Product available for research use only: